A Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Protocol
12-131
Full Title
An Open-label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
Phase
II
Purpose

Vemurafenib is approved for treating metastatic melanoma. It works by inhibiting the activity of BRAF, a protein which, when mutated, drives the growth of metastatic melanoma. Vemurafenib is approved specifically for adult patients with a BRAF mutation called V600. It is taken orally (by mouth).

In this study, researchers are assessing the effectiveness of vemurafenib for treating multiple myeloma and solid tumors other than melanoma which contain a BRAF V600 mutation, such as langerhans cell histiocytosis (LCH) and Erdheim-Chester Disease (ECD).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a solid tumor or multiple myeloma that is not responding to standard therapy or for which no standard therapy exists.
  • Patients’ cancers must contain a BRAF V600 mutation.
  • Patients must have recovered from the serious side effects of prior therapies before entering the study.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. David Hyman at 646-888-4544.

Disease(s)
Hematology: Hematologic Disorders
Hematology: Multiple Myeloma
Rare Blood Disorders